Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults aged 19 years or older~2. Patients with primary hypercholesterolemia~3. Patients who were informed about the purpose, method, effects, risks of this clinical study and have provided a written consent form signed by him/herself or by a representative~4. those who show an LDL-C level of 250 mg/dL or below and a TG level of less than 350 mg/dL at the run-in period (Week -1), and fall under the criterion of requiring the administration of antidyslipidemic drug of NCEP ATP III~Exclusion Criteria:~1. Patients with hypersensitivity to the investigational product or its ingredients~2. Those with an uncontrolled hypertension (SBP ≧ 180 mmHg or DBP ≧ 100 mmHg)~3. Those with a history of unstable angina, myocardial infarction, transient ischemic attack, cerebral vascular disease, coronary artery bypass or coronary intervention within 3 months of screening date~4. Those with a history of malignant tumor within 5 years~5. Those with a history of myopathy or rhabdomyolysis~6. Those who show clinically significant confirmed laboratory test results (1) Patients showing AST or ALT level of greater than 2 times the institutional upper limit of normal or those with active liver disease or chronic hepatitis (2) A serum creatinine level greater than 2 times the institutional upper limit of normal (3) HbA1c \> 9% (4) Those with TSH level of greater than 1.5 times the institutional upper limit of normal (5) Those with CK level greater than 2 times the institutional upper limit of normal (However, except for an increase caused by a recent trauma, intramuscular injection or strenuous exercise)~7. Those who were given, within 4 weeks prior to the baseline (8 weeks in case of fibrate) or are expected to be given during the study period, a drug that can have an effect on the efficacy assessment of the clinical study (eg: antidyslipidemic drug (statins, ezetimibe, fibrates, BAS, nicotinic acid and derivative, etc.), systemic glucocorticosteroids, steatolytic enzyme inhibitor, cyclosporine, HIV proteinase inhibitor, macrolide class antibiotics, etc.)~8. Patients who were given estrogen within 3 months from the screening or those who are expected to be given an administration during the study period. (However, a patient who is under a hormone replacement therapy (HRT) will be allowed if no dose change is expected in the course of the clinical study.)~9. Those with a history of alcohol or drug abuse~10. Patients with a hereditary disorder of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption~11. Pregnant or breast-feeding women~12. Women of childbearing potential or men who do not intend to use an adequate contraceptive measure during the study period and for 4 weeks after the end of the study(Adequate contraception: Administration and transplantation of a progestin-only contraceptive pill, intrauterine device, condom, spermicidal agent, etc.)~13. Patients who participated in another clinical study within 3 months from the screening date or have not had a washout period of at least 5 times the half-life of the active ingredient of the previously administered investigational product, whichever is longer~14. Those with drug malabsorption~15. Patients who has been judged by the investigator to be ineligible to participate in the clinical study

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RSV5mg + EZE 10mg (Type: EXPERIMENTAL): Rosuvastatin 5mg/Ezetimibe 10mg
- RSV5mg (Type: ACTIVE_COMPARATOR): Rosuvastatin 5mg
- RSV10mg + EZE10mg (Type: EXPERIMENTAL): Rosuvastatin 10mg/ Ezetimibe 10mg
- RSV10mg (Type: ACTIVE_COMPARATOR): Rosuvastatin 10mg
- RSV20mg + EZE10mg (Type: EXPERIMENTAL): Rosuvastatin 20mg/Ezetimibe 10mg
- RSV20mg (Type: ACTIVE_COMPARATOR): Rosuvastatin 20mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete